Tuberculosis chemoprophylaxis.

AUTOR(ES)

Salpeter, S

RESUMO

The incidence of tuberculosis in the United States, after decreasing for many years, has recently begun to climb at an alarming rate. This rise is due mainly to excess cases in high-risk groups including human immunodeficiency virus-infected patients, the elderly, the foreign born, and the homeless. In the United States tuberculosis has been associated with a 10% mortality despite adequate treatment. The tuberculin skin test is a safe and inexpensive test for detecting tuberculous infection. To improve its predictive value the diagnostic criteria for classifying a positive reaction have recently been revised. High-risk populations should be screened to identify those persons who would most benefit from preventive treatment. Isoniazid therapy taken for 6 to 12 months is a safe and highly effective means of preventing tuberculous infection from developing into active disease. The most worrisome toxicity of isoniazid, fatal hepatitis, is extremely rare; when patients are monitored closely the incidence of death from hepatotoxicity is less than 0.01%.

Documentos Relacionados

• Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.
• Chemoprophylaxis against tuberculosis.
• Reduction of morbidity and mortality rates for neonatal group B streptococcal disease through early diagnosis and chemoprophylaxis.
• Antimalarial agents: specific chemoprophylaxis regimens.
• Intermittent chemoprophylaxis for Pneumocystis carinii pneumonia.